Industry Awaits US Appeal Ruling On Sandoz’ Enbrel Biosimilar
Sandoz’ Erelzi Version Held Up By IP Barriers
Sandoz’ attempts to imminently break into the $5bn Enbrel market in the US rest largely on a Court of Appeals ruling that would have to reverse an unfavorable district court decision issued in August last year. A decision may be forthcoming in the next few weeks.
You may also be interested in...
In the month ahead, Mylan and Upjohn will at last begin to make final preparations for their proposed combination while second-quarter results are expected from large cap companies including Novartis’ Sandoz, Amgen, Biogen and Pfizer.
Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.